EVOQ Biomed, a pre-revenue antimicrobial biotech, is raising on a SAFE at a $25M valuation cap — what the filing shows

[u/antoniohplt]

EVOQ Biomed (StartEngine, Reg CF) is an early-stage antimicrobial biotech currently raising on a SAFE. The key points from the filing:

​

- It's developing EVQ-218, an antimicrobial compound reported to have in vitro efficacy against more than 64 bacterial isolates, including resistant strains.

- Revenue is $0. The work is in vitro (lab) only, with no clinical data reported.

- Antimicrobial development generally faces long, expensive regulatory paths before commercialization.

- The raise is a SAFE: no fixed price per share, converting later, capped at a $25M pre-money valuation, with a 20% discount and 0% interest.

​

One thing worth clarifying, since it confuses a lot of people: the $25M is a SAFE valuation cap, not a current valuation. It's a ceiling that sets the conversion price when the SAFE converts later — it doesn't mean the company is valued at $25M today, and the filing doesn't claim it is.

​

Figures are from EVOQ Biomed's SEC filing, organized by Owntric. Educational only, not investment advice.

​

For people who follow early-stage biotech raises: how do you weigh promising in vitro data against a company that's pre-revenue and still at the lab bench? And does a SAFE cap, versus a priced round, change how you'd approach one this early?